Sorafenib and Lenvatinib as first‐line treatment of hepatocellular carcinoma: A still controversial comparison
Sign Up to like & getrecommendations! Published in 2021 at "Liver International"
DOI: 10.1111/liv.14853
Abstract: I read with interest the study by CasadeiGardini et al who compared the effects of sorafenib and lenvatinib as firstline treatment of hepatocellular carcinoma (HCC) in the reallife setting, through inverse probability of treatment weighting… read more here.
Keywords: sorafenib lenvatinib; treatment hepatocellular; treatment; study ... See more keywords
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s386829
Abstract: Purpose This study aimed to investigate the incidence rate and risk factors for hepatic encephalopathy (HE) among unresectable hepatocellular carcinoma (uHCC) patients with liver cirrhosis who received sorafenib or lenvatinib treatment. Patients and Methods uHCC… read more here.
Keywords: sorafenib lenvatinib; hepatic encephalopathy; lenvatinib treatment; risk factors ... See more keywords
Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14193
Abstract: Background/Aim: We aimed to compare the outcomes between sorafenib and lenvatinib as first-line therapy for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (Vp3/4). Patients and Methods: This retrospective study enrolled 41 HCC… read more here.
Keywords: sorafenib lenvatinib; first line; therapy advanced; advanced hepatocellular ... See more keywords
Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10112890
Abstract: Sorafenib and lenvatinib are multi-targeted tyrosine kinase inhibitors which are currently approved to treat advanced hepatocellular carcinoma, renal cell carcinoma and radioiodine-refractory differentiated thyroid carcinoma. However this treatment is often limited due to common adverse… read more here.
Keywords: sorafenib lenvatinib; thyroid liver; lenvatinib; sorafenib ... See more keywords
Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27175419
Abstract: Hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM) are common clinical conditions, and T2DM is an independent risk factor for HCC. Sorafenib and lenvatinib, two multi-targeted tyrosine kinase inhibitors, are first-line therapies for advanced… read more here.
Keywords: sorafenib lenvatinib; lenvatinib rats; canagliflozin sorafenib; lenvatinib ... See more keywords